 HOUSTON, Texas and VANCOUVER, Canada, Aug. 16, 2021 PRNewswire - ESSA Pharma Inc. ESSA or the Company NASDAQ: EPIX, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2021. All references to in this release refer to United States dollars, unless otherwise indicated. 